1.76 (-%)
As of Nov 21, 2024
Source:
ESSA is a clinical stage pharmaceutical company, focused on developing novel and proprietary therapies for the treatment of prostate cancer with an initial focus on patients whose disease is progressing despite treatment with current standard of care therapies, including second-generation antiandrogen drugs such as abiraterone, enzalutamide, apalutamide, and darolutamide.
Country | United States |
Headquarters | vancouver |
Phone Number | (778) 331-0962 |
Industry | manufacturing |
CEO | David Parkinson |
Website | www.clinicaltrials.gov |